| Genomics-driven precision medicine for advanced pancreatic cancer: early results from the COMPASS trial KL Aung, SE Fischer, RE Denroche, GH Jang, A Dodd, S Creighton, ... Clinical Cancer Research 24 (6), 1344-1354, 2018 | 481 | 2018 |
| Safety and antitumor activity of pembrolizumab in advanced programmed death ligand 1–positive endometrial cancer: results from the KEYNOTE-028 study PA Ott, YJ Bang, D Berton-Rigaud, E Elez, MJ Pishvaian, HS Rugo, ... Journal of Clinical Oncology 35 (22), 2535-2541, 2017 | 450 | 2017 |
| Pembrolizumab for the treatment of programmed death–ligand 1‒positive advanced carcinoid or pancreatic neuroendocrine tumors: Results from the KEYNOTE‐028 study JM Mehnert, E Bergsland, BH O’neil, A Santoro, JHM Schellens, ... Cancer 126 (13), 3021-3030, 2020 | 113 | 2020 |
| Analytical validation of BRAF mutation testing from circulating free DNA using the amplification refractory mutation testing system KL Aung, E Donald, G Ellison, S Bujac, L Fletcher, M Cantarini, G Brady, ... The Journal of Molecular Diagnostics 16 (3), 343-349, 2014 | 60 | 2014 |
| Current status and future potential of somatic mutation testing from circulating free DNA in patients with solid tumours KL Aung, RE Board, G Ellison, E Donald, T Ward, G Clack, M Ranson, ... The HUGO journal 4, 11-21, 2010 | 59 | 2010 |
| Response to immune checkpoint inhibition in two patients with alveolar soft-part sarcoma J Lewin, S Davidson, ND Anderson, BY Lau, J Kelly, U Tabori, S Salah, ... Cancer immunology research 6 (9), 1001-1007, 2018 | 58 | 2018 |
| Preliminary results of a phase I/IIa study of BMS-986156 (glucocorticoid-induced tumor necrosis factor receptor–related gene [GITR] agonist), alone and in combination with … LL Siu, N Steeghs, T Meniawy, M Joerger, JL Spratlin, S Rottey, A Nagrial, ... Journal of Clinical Oncology 35 (15_suppl), 104-104, 2017 | 57 | 2017 |
| Pembrolizumab for patients with PD-L1–positive advanced carcinoid or pancreatic neuroendocrine tumors: results from the KEYNOTE-028 study JM Mehnert, HS Rugo, BH O'Neil, A Santoro, JHM Schellens, RB Cohen, ... Annals of Oncology 28, v142, 2017 | 56 | 2017 |
| A multi-arm phase I dose escalating study of an oral NOTCH inhibitor BMS-986115 in patients with advanced solid tumours KL Aung, AB El-Khoueiry, K Gelmon, B Tran, G Bajaj, B He, T Chen, L Zhu, ... Investigational new drugs 36, 1026-1036, 2018 | 36 | 2018 |
| Genomically personalized therapy in head and neck cancer KL Aung, LL Siu Cancers of the Head & Neck 1, 1-10, 2016 | 35 | 2016 |
| Pembrolizumab in advanced endometrial cancer: Preliminary results from the phase Ib KEYNOTE-028 study. PA Ott, YJ Bang, D Berton-Rigaud, E Elez, MJ Pishvaian, HS Rugo, ... Journal of Clinical Oncology 34 (15_suppl), 5581-5581, 2016 | 34 | 2016 |
| Phase I/IIa trial of BMS-986148, an anti-mesothelin antibody–drug conjugate, alone or in combination with nivolumab in patients with advanced solid tumors S Rottey, J Clarke, K Aung, JP Machiels, B Markman, KM Heinhuis, ... Clinical Cancer Research 28 (1), 95-105, 2022 | 29 | 2022 |
| Current methods in translational cancer research MW Lee, M Miljanic, T Triplett, C Ramirez, KL Aung, SG Eckhardt, ... Cancer and Metastasis Reviews 40, 7-30, 2021 | 29 | 2021 |
| Controlled loading of albumin-drug conjugates ex vivo for enhanced drug delivery and antitumor efficacy X Liu, RP Mohanty, EY Maier, X Peng, S Wulfe, AP Looney, KL Aung, ... Journal of controlled release 328, 1-12, 2020 | 29 | 2020 |
| Pre-encoded responsiveness to type I interferon in the peripheral immune system defines outcome of PD1 blockade therapy GM Boukhaled, R Gadalla, HJ Elsaesser, D Abd-Rabbo, R Quevedo, ... Nature immunology 23 (8), 1273-1283, 2022 | 23 | 2022 |
| Development of a circulating miRNA assay to monitor tumor burden: From mouse to man A Greystoke, M Ayub, DG Rothwell, D Morris, D Burt, CL Hodgkinson, ... Molecular oncology 10 (2), 282-291, 2016 | 23 | 2016 |
| A phase II trial of GSK2256098 and trametinib in patients with advanced pancreatic ductal adenocarcinoma (PDAC)(MOBILITY-002 Trial, NCT02428270). KL Aung, E McWhirter, S Welch, L Wang, S Lovell, LA Stayner, S Ali, ... Journal of Clinical Oncology 36 (4_suppl), 409-409, 2018 | 21 | 2018 |
| Overall survival of patients with pancreatic adenocarcinoma and BRCA1 or BRCA2 germline mutation. KL Aung, S Holter, A Borgida, A Connor, M Pintilie, NC Dhani, DW Hedley, ... Journal of Clinical Oncology 34 (15_suppl), 4123-4123, 2016 | 13 | 2016 |
| Phase II trial of trametinib and panitumumab in RAS/RAF wild type metastatic colorectal cancer K Alshammari, KL Aung, T Zhang, ARA Razak, S Serra, T Stockley, ... Clinical Colorectal Cancer 20 (4), 334-341, 2021 | 10 | 2021 |
| Metformin for pancreatic cancer KL Aung, MJ Moore The Lancet Oncology 16 (7), 748-749, 2015 | 9 | 2015 |
